Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.

Name: Kaimen Rigor review — Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.
Item: Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.
Rating: 96
Author: Alpha1

Scazufca M, Nakamura CA, Seward N, Didone TVN, Moretti FA, Oliveira da Costa M, Queiroz de Souza CH, Macias de Oliveira G, Souza Dos Santos M, Pereira LA, Mendes de Sá Martins M, van de Ven P, Hollingworth W, Peters TJ, Araya R

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.

Read full text (PMC)

DOI

10.1038/s41591-024-02864-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/35073240-3b78-4104-b9ee-e50f08702500" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/35073240-3b78-4104-b9ee-e50f08702500/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

9f557221c4ad8b39898f9c90faec4f71f2540f5aff91430698290e57e1d44b5e

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.

Paper source

Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 30 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is improvement in depressive symptomatology defined as PHQ-9 score < 10, which is a symptom scale, not a hard clinical outcome. The paper does not provide evidence of target engagement (e.g., PK/PD) or a validated link between PHQ-9 improvement and long-term clinical outcomes such as function or quality of life. The PHQ-9 is a screening tool, and the threshold of 10 is a pragmatic choice, but the paper does not cite validation that this surrogate is a reliable predictor of clinical benefit.
“The primary outcome was improvement from depressive symptomatology (PHQ-9 < 10) at 3 months.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is an absolute difference of 10.2 percentage points (42.4% vs 32.2%) in the proportion achieving PHQ-9 < 10. The paper acknowledges this is lower than the prespecified target difference of 15 percentage points. The effect is statistically significant but not anchored to a minimal clinically important difference (MCID) for PHQ-9 in this population. The authors themselves describe the effect as 'small and short-term'.
“The estimated intervention effect (10.2 percentage points in absolute terms) was lower than that specified as the original target difference (15 percentage points).”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The intervention effect is clinically meaningful.
“The estimated intervention effect (10.2 percentage points in absolute terms) was lower than that specified as the original target difference (15 percentage points).”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported pragmatic RCT of a mobile messaging intervention for depression in older adults. The design, ethics, and statistical reporting are strong, with the main weakness being vague data and code availability statements. Minor copyedit issues and a slightly overstated claim about clinical meaningfulness are noted.

Both reviewers classified the study as interventional (RCT), so no divergence. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal-related, cell lines). The statistics verification checked only a subset of tests (2 reported with sufficient detail); the rest are unverified. The claim audit flagged one overstated claim.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites global and local burden of depression in older adults, limitations of existing task-sharing programs, and the lack of evidence for self-help digital interventions in LMICs. It explicitly states the need for scalable solutions and builds the rationale for the Viva Vida intervention based on prior work (PROACTIVE). Limitations of prior research are acknowledged (e.g., need for health professional support, lack of evidence in older adults in LMICs).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“However, there is little evidence on the effectiveness of such interventions for older adults with depressive symptoms, especially in LMICs.”

paraphrase[Introduction, paragraph 4]

“It was adapted from a task-shared, collaborative care psychosocial program led by community health workers in Brazil, PROACTIVE, which improved recovery from depression at the 8-month and 12-month follow-ups.”

paraphrase[Introduction, paragraph 2]

“However, these programs often require a prominent role for health professionals, which is not feasible in health systems with few professionals who are already overstretched with other priorities.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“However, there is little evidence on the effectiveness of such interventions for older adults with depressive symptoms, especially in LMICs.”

paraphrase[Introduction, paragraph 3]

“Therefore, we developed a self-help mobile messaging intervention for older adults with substantial depressive symptoms.”

“but there were no local studies that had investigated a clinically meaningful threshold.”

MethodsFind in source

The study is a pragmatic, single-blind, individually randomized controlled trial with 1:1 allocation. Randomization used randomly permuted blocks with random block sizes, stratified by age, sex, and baseline PHQ-9 severity. Allocation was concealed via REDCap. Research assistants were blinded to allocation; participants could not be masked due to intervention nature. Sample size calculation was provided (440-500 for 80-85% power to detect 15 percentage point difference). Inclusion/exclusion criteria were pre-specified. Missing data handling was pre-specified in the SAP, with imputation and complete case analyses. The trial is registered (ReBEC).

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“The allocation sequence was generated using randomly permuted blocks with random block sizes of six, eight or ten by research team members not involved in data collection (C.A.N. and T.J.P.).”

MethodsFind in source

“Research assistants involved in recruitment and follow-up data collection were blinded to trial allocation.”

MethodsFind in source

“With an assumed attrition of 25%, 440–500 randomized individuals would yield 80–85% power to detect a 15 percentage point difference in depression improvement (PHQ-9 < 10) rates between the control and intervention arms at 3 months (25% versus 40%) using a two-sided 5% alpha.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified analysis populations.

Evidence

“The allocation sequence was generated using randomly permuted blocks with random block sizes of six, eight or ten by research team members not involved in data collection (C.A.N. and T.J.P.).”

MethodsFind in source

“Research assistants involved in recruitment and follow-up data collection were blinded to trial allocation.”

MethodsFind in source

The paper reports sex (74.8% women), age groups, education, income, hypertension, diabetes, and pharmacological treatment for depression in Table 1. Age and sex are used as stratification variables. Health status is captured via self-reported comorbidities. Since this is a human trial, species/strain and housing conditions are not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and health characteristics are well reported, including sex, age, education, income, and comorbidities.

Evidence

“Female | 225/298 (75.5) | 226/305 (74.1)”

Table 1Find in source

“Hypertension (self-reported) | 207/298 (69.5) | 222/305 (72.8)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, education, income, and comorbidities.

Evidence

“Female | 225/298 (75.5) | 226/305 (74.1)”

Table 1Find in source

“Hypertension (self-reported) | 207/298 (69.5) | 222/305 (72.8)”

Table 1Find in source

The study was approved by a named ethics committee (Comissão para Análise de Projetos de Pesquisa, ref: 4.097.596) and authorized by the Guarulhos Health Secretary. Informed verbal consent was obtained and audio-recorded. The trial was registered. Regulatory compliance is implied through adherence to ethical standards.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are adequately documented.

Evidence

“This study was approved by the ethics committee of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (Comissão para Análise de Projetos de Pesquisa, ref: 4.097.596, first approved 10 March 2021)”

MethodsFind in source

“Informed verbal consent was obtained before the screening assessment and when participants were invited to the trial, both conducted by phone. Consent was audio-recorded after authorization from the older adult.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are adequately documented.

Evidence

MethodsFind in source

The intervention is described in detail (48 audio/visual messages, content, delivery schedule). The control is a single audio message. Software used includes REDCap and Stata v.17. No antibodies, cell lines, or other bench reagents are applicable. The intervention is the key resource and is adequately described.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (Viva Vida intervention) is described in detail, and software tools are identified.

Evidence

“A total of 48 audio or visual messages were automatically sent 4 days a week for 6 weeks (one in the morning, one in the afternoon).”

MethodsFind in source

“Statistical tests were two-sided and all analyses were conducted using Stata v.17 (StataCorp LLC).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (Viva Vida intervention) is described in detail, and software tools are identified.

Evidence

“A total of 48 audio or visual messages were automatically sent 4 days a week for 6 weeks (one in the morning, one in the afternoon).”

MethodsFind in source

“all analyses were conducted using Stata v.17 (StataCorp LLC).”

Statistical analysisFind in source

The paper names statistical tests (logistic regression, linear regression, CACE analysis), reports exact p-values (e.g., P = 0.019), and provides effect sizes with 95% CIs. Assumptions are addressed (Box-Tidwell test, residual plots). Software is identified. Data presentation includes per-group n and percentages. Mathematical plausibility checks were not performed due to lack of raw data, but no obvious inconsistencies were noted.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“The adjusted odds ratio (OR) for this improvement, after imputing missing values, was 1.57 (95% CI = 1.07–2.29; P = 0.019).”

ResultsFind in source

“10.2 (2.0–18.4) | 1.57 (1.07–2.29) | 0.019”

Table 2Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“The adjusted odds ratio (OR) for this improvement, after imputing missing values, was 1.57 (95% CI = 1.07–2.29; P = 0.019).”

ResultsFind in source

“The Box–Tidwell test was run after the logistic regression models to test whether the logit transform was a linear function of the predictors for the different models. Normality assumptions for linear regression models were evaluated through residual plots.”

Statistical analysisFind in source

The data availability statement says de-identified individual participant data will be made available 24 months after publication, with proposals directed to the corresponding author. This is a managed-access statement but lacks details on the review process or timeframe. Code availability similarly states code will be made available 24 months after publication, but no repository or identifier is given. No accession numbers are provided.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data and code availability statements are present but vague, lacking a concrete access mechanism.

Evidence

“De-identified individual participant data and the data dictionary will be made available 24 months after publication. Proposals with specific aims and an analysis plan should be directed to the corresponding author (M.S.).”

Data availabilityFind in source

“The code for the data analysis will also be made available 24 months after publication.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data and code availability statements are present but vague, lacking a concrete access mechanism.

Evidence

Data availabilityFind in source

“The code for the data analysis will also be made available 24 months after publication.”

Data availabilityFind in source

The trial is registered (ReBEC RBR-4c94dtn). A CONSORT diagram is provided. All pre-specified outcomes are reported, including null results. Limitations are discussed in detail. Conclusions are proportional to the evidence. Funding and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with a registered trial, CONSORT diagram, and discussion of limitations.

Evidence

“Brazilian Registry of Clinical Trials registration: ReBEC ( RBR-4c94dtn (https://ensaiosclinicos.gov.br/rg/RBR-4c94dtn) ).”

AbstractFind in source

“In addition to the issue of the lower magnitude of the observed difference in absolute terms (and some of the values in the relevant CI) compared with the target difference as discussed above, this study has some important limitations.”

Discussion ¶8Find in source

PASSReviewer 2· 90% conf

The manuscript is transparent with trial registration, CONSORT flow, limitations, and funding/COI statements.

Evidence

“Brazilian Registry of Clinical Trials registration: ReBEC ( RBR-4c94dtn (https://ensaiosclinicos.gov.br/rg/RBR-4c94dtn) ).”

AbstractFind in source

“this study has some important limitations.”

Discussion ¶8Find in source

Registration stated in text, but no registry ID was detected. Reporting guideline cited: CONSORT.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 42 references by DOI: 36 verified — 6 no DOI (shown, not verified).

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly clarity, consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and generally trustworthy, but readers should weigh the vague data/code availability and the slightly overstated claim of clinical meaningfulness. An erratum or clarification could address the availability statements and temper the claim.

1.
HIGHdata code
In the Data availability statement, specify a concrete access mechanism such as a named repository (e.g., Dryad, Zenodo) or a managed-access platform (e.g., Vivli) with conditions and a clear timeline, instead of only directing proposals to the corresponding author.
The current statement is vague and does not meet reproducibility standards; a concrete route is needed for readers to access the data.
2.
HIGHdata code
In the Code availability statement, provide a public repository (e.g., GitHub, Zenodo) with a DOI or permanent identifier for the analysis code.
Stating code will be available '24 months after publication' without a repository is insufficient for reproducibility.
3.
HIGHrigor
In the Discussion, temper the claim that the intervention effect is clinically meaningful, given the observed absolute difference (10.2 percentage points) was lower than the pre-specified target (15 percentage points).
The claim audit flagged this as overstated; the evidence does not fully support clinical meaningfulness as originally claimed.
4.
MEDIUMcopyedit
Fix the typo 'seperately' to 'separately' in the Extended Data Table 6 footnote.
Typographical errors undermine professionalism and clarity.
5.
MEDIUMcopyedit
Rephrase the awkward sentence in the Discussion about attrition risk for clarity, e.g., 'A further limitation is the risk of bias through attrition, albeit at about half the level accounted for in our sample size calculation (about 12.5% overall compared with the 25% allowed for).'
The current sentence structure is confusing and could be misinterpreted.
6.
LOWcopyedit
Ensure consistent spacing around 'n' in the Abstract (e.g., 'n = 298' vs 'n = 305').
Minor formatting inconsistency that should be corrected for polish.

Full text (57,343 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.

Read full text (PMC)

DOI

10.1038/s41591-024-02864-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/35073240-3b78-4104-b9ee-e50f08702500" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/35073240-3b78-4104-b9ee-e50f08702500/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

9f557221c4ad8b39898f9c90faec4f71f2540f5aff91430698290e57e1d44b5e

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 30 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is improvement in depressive symptomatology defined as PHQ-9 score < 10, which is a symptom scale, not a hard clinical outcome. The paper does not provide evidence of target engagement (e.g., PK/PD) or a validated link between PHQ-9 improvement and long-term clinical outcomes such as function or quality of life. The PHQ-9 is a screening tool, and the threshold of 10 is a pragmatic choice, but the paper does not cite validation that this surrogate is a reliable predictor of clinical benefit.
“The primary outcome was improvement from depressive symptomatology (PHQ-9 < 10) at 3 months.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is an absolute difference of 10.2 percentage points (42.4% vs 32.2%) in the proportion achieving PHQ-9 < 10. The paper acknowledges this is lower than the prespecified target difference of 15 percentage points. The effect is statistically significant but not anchored to a minimal clinically important difference (MCID) for PHQ-9 in this population. The authors themselves describe the effect as 'small and short-term'.
“The estimated intervention effect (10.2 percentage points in absolute terms) was lower than that specified as the original target difference (15 percentage points).”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The intervention effect is clinically meaningful.
“The estimated intervention effect (10.2 percentage points in absolute terms) was lower than that specified as the original target difference (15 percentage points).”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit4 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

4 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“However, there is little evidence on the effectiveness of such interventions for older adults with depressive symptoms, especially in LMICs.”

paraphrase[Introduction, paragraph 4]

paraphrase[Introduction, paragraph 2]

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“However, there is little evidence on the effectiveness of such interventions for older adults with depressive symptoms, especially in LMICs.”

paraphrase[Introduction, paragraph 3]

“Therefore, we developed a self-help mobile messaging intervention for older adults with substantial depressive symptoms.”

“but there were no local studies that had investigated a clinically meaningful threshold.”

MethodsFind in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“The allocation sequence was generated using randomly permuted blocks with random block sizes of six, eight or ten by research team members not involved in data collection (C.A.N. and T.J.P.).”

MethodsFind in source

“Research assistants involved in recruitment and follow-up data collection were blinded to trial allocation.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified analysis populations.

Evidence

“The allocation sequence was generated using randomly permuted blocks with random block sizes of six, eight or ten by research team members not involved in data collection (C.A.N. and T.J.P.).”

MethodsFind in source

“Research assistants involved in recruitment and follow-up data collection were blinded to trial allocation.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and health characteristics are well reported, including sex, age, education, income, and comorbidities.

Evidence

“Female | 225/298 (75.5) | 226/305 (74.1)”

Table 1Find in source

“Hypertension (self-reported) | 207/298 (69.5) | 222/305 (72.8)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, education, income, and comorbidities.

Evidence

“Female | 225/298 (75.5) | 226/305 (74.1)”

Table 1Find in source

“Hypertension (self-reported) | 207/298 (69.5) | 222/305 (72.8)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are adequately documented.

Evidence

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are adequately documented.

Evidence

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (Viva Vida intervention) is described in detail, and software tools are identified.

Evidence

“A total of 48 audio or visual messages were automatically sent 4 days a week for 6 weeks (one in the morning, one in the afternoon).”

MethodsFind in source

“Statistical tests were two-sided and all analyses were conducted using Stata v.17 (StataCorp LLC).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (Viva Vida intervention) is described in detail, and software tools are identified.

Evidence

“A total of 48 audio or visual messages were automatically sent 4 days a week for 6 weeks (one in the morning, one in the afternoon).”

MethodsFind in source

“all analyses were conducted using Stata v.17 (StataCorp LLC).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“The adjusted odds ratio (OR) for this improvement, after imputing missing values, was 1.57 (95% CI = 1.07–2.29; P = 0.019).”

ResultsFind in source

“10.2 (2.0–18.4) | 1.57 (1.07–2.29) | 0.019”

Table 2Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“The adjusted odds ratio (OR) for this improvement, after imputing missing values, was 1.57 (95% CI = 1.07–2.29; P = 0.019).”

ResultsFind in source

Statistical analysisFind in source

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data and code availability statements are present but vague, lacking a concrete access mechanism.

Evidence

Data availabilityFind in source

“The code for the data analysis will also be made available 24 months after publication.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data and code availability statements are present but vague, lacking a concrete access mechanism.

Evidence

Data availabilityFind in source

“The code for the data analysis will also be made available 24 months after publication.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with a registered trial, CONSORT diagram, and discussion of limitations.

Evidence

“Brazilian Registry of Clinical Trials registration: ReBEC ( RBR-4c94dtn (https://ensaiosclinicos.gov.br/rg/RBR-4c94dtn) ).”

AbstractFind in source

Discussion ¶8Find in source

PASSReviewer 2· 90% conf

The manuscript is transparent with trial registration, CONSORT flow, limitations, and funding/COI statements.

Evidence

“Brazilian Registry of Clinical Trials registration: ReBEC ( RBR-4c94dtn (https://ensaiosclinicos.gov.br/rg/RBR-4c94dtn) ).”

AbstractFind in source

“this study has some important limitations.”

Discussion ¶8Find in source

Registration stated in text, but no registry ID was detected. Reporting guideline cited: CONSORT.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 42 references by DOI: 36 verified — 6 no DOI (shown, not verified).

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly clarity, consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data availability statement, specify a concrete access mechanism such as a named repository (e.g., Dryad, Zenodo) or a managed-access platform (e.g., Vivli) with conditions and a clear timeline, instead of only directing proposals to the corresponding author.
The current statement is vague and does not meet reproducibility standards; a concrete route is needed for readers to access the data.
2.
HIGHdata code
In the Code availability statement, provide a public repository (e.g., GitHub, Zenodo) with a DOI or permanent identifier for the analysis code.
Stating code will be available '24 months after publication' without a repository is insufficient for reproducibility.
3.
HIGHrigor
In the Discussion, temper the claim that the intervention effect is clinically meaningful, given the observed absolute difference (10.2 percentage points) was lower than the pre-specified target (15 percentage points).
The claim audit flagged this as overstated; the evidence does not fully support clinical meaningfulness as originally claimed.
4.
MEDIUMcopyedit
Fix the typo 'seperately' to 'separately' in the Extended Data Table 6 footnote.
Typographical errors undermine professionalism and clarity.
5.
MEDIUMcopyedit
Rephrase the awkward sentence in the Discussion about attrition risk for clarity, e.g., 'A further limitation is the risk of bias through attrition, albeit at about half the level accounted for in our sample size calculation (about 12.5% overall compared with the 25% allowed for).'
The current sentence structure is confusing and could be misinterpreted.
6.
LOWcopyedit
Ensure consistent spacing around 'n' in the Abstract (e.g., 'n = 298' vs 'n = 305').
Minor formatting inconsistency that should be corrected for polish.

Full text (57,343 chars)Analyzed: Aug 16, 2026